Exploring new strategies, focusing on crosstalk among the various normal and neoplastic cell types present in the TME, including the use of specific molecular and pharmacologic approaches to inhibit the function of key tumor progression genes (e.g., SERPINE1), may have clinical utility e.g., [118,158,159,160,161]. The gene discussed is SERPINE1; the disease is neoplasm.